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Introduction: Epidermal growth factor receptor (EGFR) mutation 
T790M accounts for approximately half of acquired resistances to 
EGFR-tyrosine kinase inhibitor (TKI). Because T790M is mediated by 
TKI exposure, its penetration and “on–off ” may affect T790M status.
Methods: We retrospectively reviewed T790M status and clini-
cal course of patients who had undergone multiple rebiopsies after 
acquired resistance to EGFR-TKI.
Results: Of 145 patients with EGFR-mutant NSCLC receiving rebi-
opsy after acquired resistance, 30 underwent multiple site rebiopsies, 
and 24 received repeated rebiopsies at the same lesion. In 22 patients 
who underwent rebiopsies from both central nervous system (CNS; 20 
cerebrospinal fluids [CSF] and 2 brain tumoral tissues) and thoracic 
lesions (7 lung tissues, 14 pleural effusions, and 1 lymph node), 12 
were thoracic-T790M-positive. Of these 12 patients, 10 were CNS-
T790M-negative, despite exhibiting thoracic-T790M-positive. All 10 
thoracic-T790M-negatives were CNS-T790M-negative. Three patients 
revealed a spatial heterogeneous T790M status among their thoracic 
lesions. In 24 patients receiving repeated rebiopsies at the same lesion 
(12 lung tissues, 6 CSFs, and 6 pleural effusions), T790M status of lung 
lesions varied in ﬁve patients after TKI-free interval. In all ﬁve patients 
whose T790M status changed from positive to negative, EGFR-TKI 
rechallenge was effective. In three of these ﬁve patients, after further 
TKI exposure, T790M status changed from negative to positive again. 
There was also a patient whose CSF T790M status changed from nega-
tive to positive after high-dose erlotinib therapy.
Conclusions: T790M status in an individual patient can be spa-
tiotemporally heterogeneous because of selective pressure from 
EGFR-TKI.
Key Words: Epidermal growth factor receptor mutation, T790M, 
Epidermal growth factor receptor-tyrosine kinase inhibitor, Acquired 
resistance, Rebiopsy.
(J Thorac Oncol. 2015;10: 1553–1559)
Lung cancer is the leading cause of cancer deaths world-wide. Non–small-cell lung cancer (NSCLC) accounts for 
approximately 80% of lung cancers, and the majority are 
already unresectable and metastatic upon their initial diag-
nosis. Cytotoxic chemotherapies such as platinum-based 
regimens were once the primary therapeutic option for meta-
static NSCLC, but their advancement has reached a plateau. 
Molecular-targeted therapies have been recently developed, 
and they have provided a remarkable beneﬁt to patients har-
boring speciﬁc genetic alterations such as epidermal growth 
factor receptor (EGFR) gene mutations or anaplastic lym-
phoma kinase gene fusions.1 Somatic mutations in the EGFR 
have been identiﬁed in patients with radiographic responses to 
EGFR-tyrosine kinase inhibitors (TKIs).2,3 Currently, the efﬁ-
cacy of up-front EGFR-TKIs has been established for patients 
harboring EGFR sensitive mutations in prospective random-
ized phase III trials, and the median progression-free survivals 
(PFSs) are approximately 12 months.4–10
Despite an initial dramatic response, most patients 
receiving EGFR-TKI acquire resistance to EGFR-TKI. 
Several acquired resistant mechanisms to EGFR-TKI have 
been identiﬁed,11–16 and the “gatekeeper” EGFR mutation, a 
threonine-to-methionine substitution at amino acid position 
790 in exon 20 (T790M), is the most common mechanism 
and accounts for approximately half of acquired resistance to 
EGFR-TKI. T790M causes TKI resistance by increasing ade-
nosine triphosphate (ATP) afﬁnity, thus outcompeting TKI 
Spatiotemporal T790M Heterogeneity in Individual Patients 
with EGFR-Mutant Non–Small-Cell Lung Cancer after 
Acquired Resistance to EGFR-TKI
Akito Hata, MD,* Nobuyuki Katakami, MD, PhD,* Hiroshige Yoshioka, MD, PhD,† Reiko Kaji, MD,* 
Katsuhiro Masago, MD, PhD,* Shiro Fujita, MD, PhD,* Yukihiro Imai, MD, PhD,* Akihiro Nishiyama, MD,† 
Tadashi Ishida, MD, PhD,† Yoshihiro Nishimura, MD, PhD,‡ and Yasushi Yatabe, MD, PhD§
*Division of Integrated Oncology, Institute of Biomedical Research and 
Innovation, Kobe, Japan; †Department of Respiratory Medicine, 
Kurashiki Central Hospital, Kurashiki, Japan; ‡Department of 
Respiratory Medicine, Kobe University School of Medicine, Kobe, Japan; 
and §Department of Pathology and Molecular Diagnostics, Aichi Cancer 
Center Hospital, Nagoya, Japan.
Disclosure: Dr. Katakami received grants from Astra Zeneca, Eisai, Ono, 
Kyowa Kirin, Shionogi, Daiichi-Sankyo, Taiho, Chugai, Eli Lilly, 
Boeringer Ingelheim, and Merck Serono and payment for lectures from 
Dainippon Sumitomo, Chugai, Boeringer Ingelheim, Astra Zeneca, Eli 
Lilly, Taiho, Janssen, Novartis, Pﬁzer, Ono, and Daiichi-Sankyo. Dr. 
Yoshioka received payment for lectures from Chugai, Eli Lilly, Pﬁzer, and 
Astra Zeneca. Dr. Nishimura received payment for reviewing the manu-
script from Teijin Limited and provision of medicines from Boeringer 
Ingelheim. Dr. Yatabe received payment for lectures from AstraZeneca, 
Pﬁzer, Chugaipharm, Novartis, and Roche. The other authors declare no 
conflicts of interest.
The study was partially supported by research assistance funds from 
Shinryokukai General Incorporated Association.
Address for correspondence: Akito Hata, Division of Integrated Oncology, 
Institute of Biomedical Research and Innovation, 2-2, Minatojima-
minamimachi, Chuo-ku, Kobe 650-0047, Japan. E-mail: a-hata@fbri.org
DOI: 10.1097/JTO.0000000000000647
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/15/1011-1553
ORIGINAL ARTICLE
1554 Copyright © 2015 by the International Association for the Study of Lung Cancer
Hata et al. Journal of Thoracic Oncology ® • Volume 10, Number 11, November 2015
in ATP binding pocket.17 T790M was initially considered as 
a secondary mutation following progression on EGFR-TKI 
therapy, but several recent reports suggested that T790M actu-
ally existed at a low frequency before EGFR-TKI therapy.18,19 
Moreover, using highly sensitive methods, the frequencies of 
T790M have been reported ranging from 40% to 79% even in 
EGFR-TKI naive NSCLC patients harboring EGFR sensitive 
mutations.20–22 These results suggest that minor population of 
T790M-positive cancer cells may intrinsically exist in EGFR-
mutated tumors. Preclinically, T790M is mediated by TKI 
exposure, whereas TKI withdrawal reduces the proportion of 
T790M-positive cells in an EGFR-mutated tumor.23 Resistant 
tumors are likely to be a mixed population of TKI-sensitive 
(T790M-negative) and TKI-resistant (T790M-positive) cells, 
and T790M status in a tumor is subject to selective pressure 
from EGFR-TKI.24 We thus hypothesized that T790M status 
in an individual patient was heterogenous because of selec-
tive pressure from EGFR-TKI. Tumor T790M status could be 
spatiotemporally distinct according to cancer locations and 
presence of TKI exposure.
The aim of this study was to analyze dynamic varia-
tion of T790M status and clinical course of patients who had 




The study is a retrospective study on which patient 
data were collected from two institutes (Institute of 
Biomedical Research and Innovation Hospital, Kobe, Japan 
and Kurashiki Central Hospital, Kurashiki, Japan). We 
reviewed T790M status and clinical course of patients who 
had undergone multiple rebiopsies by the electronic medical 
records. The patients were in advanced stage (stage IIIb, IV, 
or recurrence after surgery) NSCLC with EGFR sensitive 
mutations. They had undergone EGFR-TKI therapies and 
represented acquired resistance to EGFR-TKIs. Acquired 
resistance was deﬁned as Jackman et al.25 proposed. In 
their criteria, response or durable stable disease (≥6 mo) 
was conﬁrmed on EGFR-TKI therapies. Informed consent 
regarding the EGFR mutational analysis was obtained from 
all patients. The study was approved by the institutional 
review board.
Rebiopsy and EGFR Mutational Analysis
Rebiopsies were performed on various sites using vari-
ous procedures. Lung tumors and pleural dissemination were 
rebiopsied using computed tomography–guided percutane-
ous core needle biopsy or transbronchial lung biopsy with 
flexible bronchoscopy. Pleural/pericardial effusion was col-
lected by thoraco/pericardial centesis. To rebiopsy super-
ﬁcial lymph node metastases, we used ultrasound-guided 
percutaneous core needle biopsy. Lumbar puncture was per-
formed to obtain cerebrospinal fluid (CSF). Brain tumors, 
an abdominal lymph node, and a skin tumor were surgically 
taken, not for rebiopsy, but for local palliation. We isolated 
tumor DNA from each malignant cell conﬁrmed specimen 
and analyzed EGFR sensitive mutations and T790M muta-
tion using highly sensitive assay: the peptide nucleic 
acid–locked nucleic acid polymerase chain reaction clamp 
method26 or the cycleave method.27 Similar sensitivities of 
these two EGFR mutational tests were demonstrated.28 No 
other acquired resistant molecular mechanisms (e.g., MET) 
were examined.
Postprogression Survival and T790M Analysis
To investigate the patient prognosis after initial EGFR-
TKI failure, we examined the periods of postprogression sur-
vival (PPS) after initial EGFR-TKI failure. We sorted PPS 
according to T790M status.
Statistical Analyses
The progressive disease (PD) of EGFR-TKI therapy 
was judged by each physician in charge, according to clini-
cal progression or objective progression as described by the 
Response Evaluation Criteria in Solid Tumors, version 1.1. 
PFS was deﬁned as the length of time from the initiation of the 
EGFR-TKI therapy until PD or death. PPS was deﬁned as the 
date of the PD on initial EGFR-TKI until death. PPS curves 
were estimated according to the Kaplan–Meier method. PPSs 
were compared using the log-rank test. A p value less than 
0.05 was considered signiﬁcant. The statistical analyses were 
performed using JMP 7 (SAS Institute, Inc., Cary, NC).
RESULTS
Patient Characteristics
Between May 2008 and February 2015, 145 patients 
with EGFR-mutant NSCLC received rebiopsy after acquired 
resistance to EGFR-TKI in our institutes. Of 145 patients, 
30 underwent rebiopsies at multiple sites, and 24 received 
repeated rebiopsies at the same lesion. The patient character-
istics are shown in Table 1. Eleven patients were duplicated in 
both cohorts.
T790M Status and PPS in Patients Who 
Received Rebiopsies at Multiple Sites
T790M status and PPS in 30 patients who received rebi-
opsies at multiple sites are shown in Table 2. Of 22 patients 
(1–22) who underwent rebiopsies from both CNS (20 CSF 
and 2 brain tumoral tissue) and thoracic lesions (7 lung 
tumors, 14 pleural effusions, and 1 lymph node), 12 patients 
(1–12) revealed T790M-positive thoracic lesions. Of these 12 
patients, all 10 CSF samples (3–12) were T790M-negative 
and 2 brain tumoral tissues (1 and 2) were T790M-positive. 
Conversely, all 10 T790M-negative patients (13–22) in tho-
racic lesions revealed T790M-negative CNS lesions.
Figure 1 shows PPSs according to T790M status. 
Median PPS of 10 patients with T790M CNS/thoracic double-
negative was 20.1 (95% conﬁdence interval [CI], 3.9–26.0) 
months, and that of 10 patients with T790M CNS-negative/
thoracic-positive was 11.2 (95% CI, 4.3–22.6) months 
(p = 0.0663). Median PPS was 58.9 months in the two patients 
with T790M thoracic/CNS double-positive.
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In patient 24, T790M was positive in the primary lung 
tumor, but negative in a metastatic lung nodule. In patients 
25 and 26, despite T790M being negative in the primary lung 
tumor, T790M was positive in the pleural effusion.
T790M Status and TKI Exposure in 
Patients Who Received Repeated 
Rebiopsies at the Same Site
T790M status and TKI exposure in 24 patients who 
received repeated rebiopsies at the same site are shown in 
Table 3. T790M status of lung lesions varied in ﬁve patients 
after TKI-free interval. In all ﬁve patients whose T790M sta-
tus changed from positive to negative, EGFR-TKI rechallenge 
was effective. In three of these ﬁve patients, after progression 
on TKI rechallenge therapy, T790M status changed from neg-
ative to positive again.
Almost all (18 of 19 initial T790M-negative patients 
except patient 41) T790M-negative patients at the initial rebi-
opsy remained T790M-negative at further rebiopsies. There 
was a patient (41) whose CSF T790M status changed from 
negative to positive after high-dose erlotinib therapy.
Efficacy of EGFR-TKI Rechallenge 
after T790M Disappearance
Five patients underwent EGFR-TKI rechallenge after 
T790M disappearance as shown in Table 4. Response rate, 
disease control rate, median PFS, and median PPS were 80%, 
100%, 6.0 (95% CI, 1.3–5.7) months, and not reached, respec-
tively. In four (24, and 31–33) of the ﬁve patients, T790M 
remained positive on rebiopsy 6 months after TKI withdrawal, 
but changed to negative over 12 months after TKI withdrawal 
(Table 3). These four patients underwent geﬁtinib rechallenge 
over 1 year after TKI-free interval with T790M disappearance 
and obtained better clinical beneﬁt from geﬁtinib.
DISCUSSION
T790M is not only a resistant mechanism but also a 
clinically signiﬁcant biomarker after acquired resistance to 
EGFR-TKI. Several reports demonstrated that emergence 
of T790M was a favorable prognostic marker after acquired 
resistance.29,30 Upcoming third-generation EGFR-TKIs have 
shown remarkable effectiveness for patients with T790M after 
acquired resistance to classical EGFR-TKIs.31,32 T790M has 
become an important predictive marker for third-generation 
EGFR-TKIs, as well as a prognostic marker after acquired 
resistance. We herein demonstrate that T790M status in an 
individual patient can be spatiotemporally heterogeneous 
because of selective pressure from EGFR-TKI. Some investi-
gators have also shown spatial33 and temporal34,35 T790M het-
erogeneity, suggesting its reproducibility. Medical oncologists 
should recognize this spatiotemporal T790M heterogeneity 
and not miss an opportunity to apply third-generation EGFR-
TKI therapy for patients after acquired resistance to classical 
EGFR-TKIs.
Results of multiple site rebiopsies revealed spatial 
T790M heterogeneity. T790M status was frequently dis-
tinct between CNS (especially CSF) and thoracic lesions in 
individual patients. Several studies reported that poor TKI 
penetration into CNS results in pharmacokinetic failure of 
EGFR-TKI.24 Because T790M is mediated by TKI exposure, 
poor TKI penetration into CNS is likely to be associated with 
low incidence of T790M in CNS. Accordingly, our results 
demonstrated low incidence of T790M in the CSF lesions, 
despite T790M-positive status in the thoracic lesions.
T790M-positive patients seem to have a better progno-
sis than T790M-negative patients after acquired resistance to 
EGFR-TKI.29,30 In our results, PPS in patients with T790M 
CNS/thoracic double-negative was similar to that of T790M 
CNS-negative/thoracic-positive. Markedly long survival was 
achieved in the two patients (1 and 2) with T790M CNS/thoracic 
double-positive. These results suggest even if T790M is posi-
tive in thoracic lesions, T790M-negative status in CNS causes 
poorer prognosis. We previously showed T790M-negative sta-
tus and leptomeningeal metastases were associated with poorer 
prognosis after acquired resistance to EGFR-TKI.36 Insufﬁcient 
TKI exposure may induce an invasion of rapid growth T790M-
negative cells into CNS, resulting in poorer prognosis. In a 
TABLE 1. Patient Characteristics
Characteristics





  ≥70 5 8
  <70 25 16
Gender
  Male 5 6
  Female 25 18
Smoking history
  Never 19 14
  Former/current 11 10
Histology (initial rebiopsy)
  Adenocarcinoma 29 22
  Other 1 (Sq) 2 (Sq/LCNEC)
Types of EGFR mutation
  Exon 19 (deletion) 13 6
  Exon 21 (L858R) 15 16
  G719X/L861Q 2/0 1/1
Initial TKI
  Geﬁtinib 21 17
  Erlotinib/afatinib 9/0 6/1
Response to Initial TKI
  CR/PR 2/19 1/15
  SD 9 8
Line of initial TKI
  First 9 4
  Second or later 21 20
PFS with initial TKI
  ≥10 mo 19 12
  <10 mo 11 12
Eleven patients were duplicated in both cohorts.
Sq, squamous; LCNEC, large-cell neuroendcrine carcinoma; EGFR, epidermal 
growth factor receptor; TKI, tyrosine kinase inhibitor; CR, complete response; PR, 
partial response; SD, stable disease; PFS, progression-free survival.
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patient (41) with leptomeningeal metastases, CSF T790M 
status changed from negative to positive after high-dose erlo-
tinib therapy. High-dose erlotinib might enable a sufﬁcient TKI 
exposure into CSF, inducing the T790M mutation. This case 
indicates the potential of high-dose EGFR-TKI therapy, and 
some reports suggested its effectiveness.37–39
Three patients (24–26) exhibited an intrathoracic T790M 
heterogeneity (a portion of patient 24’s clinical course was 
previously reported).40 Because of this spatial heterogeneity, 
actual T790M-positive patients could be regarded as T790M-
negative, and they might not be treated with third-generation 
EGFR-TKIs. Thoracic lesions are the most frequent target of 
rebiopsy for lung cancer patients after acquired resistance to 
EGFR-TKI. We should understand the possibility of intratho-
racic T790M heterogeneity and carefully judge the T790M 
status of the patient after acquired resistance.
Temporal T790M heterogeneity was shown in results of 
repeated rebiopsies. T790M status of the lung lesion varied in 
some T790M-positive patients, depending on TKI exposure. 
On the other hand, almost all T790M-negative patients at the 
initial rebiopsy remained T790M-negative at further rebiop-
sies. This phenomenon implies that T790M-associated EGFR-
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FIGURE 1. Postprogression survival according to T790M status.
TABLE 2. T790M Status and PPS in Patients Who Received Rebiopsies at Multiple Sites
Patient Age/Sex Sensitive Mutation Biopsy Site 1/T790M (+/−) Biopsy Site 2/T790M (+/−) Biopsy Site 3/T790M (+/−) PPS (mo)
1 62/F Del-19 Lung tumor/+ Brain tumor/+ 43.5+
2 58/F Del-19 Lung tumor/+ Brain tumor/+ 58.9
3 53/F L858R Lung tumor/+ CSF/− 11.2
4 60/F G719S Pleural effusion/+ CSF/− 22.6
5 53/M Del-19 Pleural effusion/+ CSF/− 30.5
6 57/M L858R Pleural effusion/+ CSF/− 4.3
7 56/F Del-19 Pleural effusion/+ CSF/− 7.6
8 74/M Del-19 Pleural effusion/+ CSF/− 10.4
9 76/F Del-19 Pleural effusion/+ CSF/− 34.0
10 79/F Del-19 Pleural effusion/+ CSF/− 9.0
11 65/F L858R Pleural effusion/+ CSF/− 16.5
12 52/F L858R Pleural effusion/+ CSF/− 7.4
13 63/F L858R Lung tumor/− CSF/− 36.0
14 69/M L858R Lung tumor/− CSF/− 49.9
15 49/F Del-19 Lung tumor/− CSF/− 20.1
16 61/F L858R Lung tumor/− CSF/− 24.6
17 69/F G719S Pleural effusion/− CSF/− 4.3
18 67/F Del-19 Pleural effusion/− CSF/− 8.1
19 81/F Del-19 Pleural effusion/− CSF/− 11.0
20 67/F L858R Pleural effusion/− CSF/− 3.9
21 66/F Del-19 Pleural effusion/− CSF/− 59.0
22 67/F L858R Clavicular LN/− CSF/− 11.4
23 66/F L858R Lung tumor/+ Pleural effusion/+ 14.0+
24 61/M L858R Lung (primary)/+ Lung (meta)/− 48.0+
25 62/F Del-19 Lung tumor/− Pleural effusion/+ Pleural DIS/+ 15.5+
26 55/F Del-19 Lung tumor/− Pleural effusion/+ Inguinal LN/− 14.8
27 57/F L858R Abdominal LN/− Skin tumor/− 3.5
28 80/F L858R Lung tumor/− Pleural effusion/− 27.4
29 61/F L858R Lung tumor/− Clavicular LN/− 33.4+
30 55/F L858R Lung tumor/− Pericardial effusion/− 31.7+
PPS, postprogression survival; F, female; M, male; CSF, cerebrospinal fluid; DIS, dissemination; LN, lymph node; F, female; M, male.
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T790M-positive patients, T790M-positive and T790M-
negative cancer cells coexist, and TKI selective pressure may 
dominate their existence ratio, determining the total tumor’s 
T790M status. Meanwhile, in intrinsically T790M-negative 
patients, TKI selective pressure may never induce T790M-
positive cancer cells.
In our ﬁve patients receiving TKI rechallenge, TKI 
was notably effective after T790M disappearance. Several 
studies showed the efﬁcacy of TKI rechallenge,41–43 but their 
efﬁcacies were moderate. Some patients can deﬁnitely obtain 
much higher clinical beneﬁt from TKI rechallenge, and it is 
important to identify such patients. Preclinically, Chmielecki 
et al.23 demonstrated that T790M is mediated by TKI expo-
sure, and TKI withdrawal reduces the proportion of T790M-
harboring cells. Oxnard et al.24 proposed that resistant 
tumors are likely to be a mixed population of TKI-sensitive 
and TKI-resistant cells, and upon withdrawal of the selec-
tive pressure from TKI, previously arrested TKI-sensitive 
TABLE 3. T790M Status and TKI Exposure in Patients Who Received Repeated Rebiopsies at the Same Site
Patient Age/Sex Sensitive Mutation Rebiopsy Site
T790M Status and TKI  
Exposure, +, T790M-positive; −, T790M-negative PPS (mo)
24 61/M L858R Lung (−) ➔ G ➔ + ⇒ − ➔ G ➔ + ⇒ + ⇒ − ➔ G ➔ + ➔ A + B ➔ 48.0+
31 82/M L858R Lung (−) ➔ G ➔ + ⇒ + ⇒ − ➔ G ➔ + ➔ G ➔ + ➔ III ➔ 34.1+
32 73/F L858R Lung + (de novo) ⇒ (−) ➔ G ➔ + ⇒ + ⇒ − ➔ G ➔ + ➔ III ➔ 24.9+
33 76/F Del-19 Lung (−) ➔ G ➔ + ⇒ + ⇒ − ➔ G ➔ † 25.5
34 84/M L858R Lung (−) ➔ G ➔ + ⇒ − ➔ E ➔ † 13.3
35 62/F Del-19 Lung (−) ➔ E ➔ + ⇒ + ⇒ 52.5+
36 75/F L858R Lung (−) ➔ G ➔ − ⇒ − ⇒ − ➔ E ➔ − ⇒ † 22.0
37 60/F L858R Lung (−) ➔ A ➔ − ➔ E ➔ − ⇒ † 24.6
38 69/M L858R Lung (−) ➔ G ➔ − ➔ E ➔ − ⇒ † 49.8
29 61/F L858R Lung (−) ➔ G, E ➔ − ⇒ − ➔ E ➔ 33.4+
28 80/F L858R Lung (−) ➔ G ➔ − ➔ E + B ➔ − ⇒ † 27.4
30 55/F L858R Lung (−) ➔ E ➔ − ➔ E + B ➔ − ⇒ 22.7+
23 66/F L858R PE (−) ➔ E ➔ + ➔ A ➔ + ➔ III ➔ 15.5+
25 61/F Del-19 PE (−) ➔ G ➔ + ⇒ + ➔ III ➔ 30.0+
5 53/M Del-19 PE (−) ➔ G ➔ + ➔ E ➔ + ➔ E ➔ † 30.5
26 55/F Del-19 PE (−) ➔ E ➔ + ➔ A + B ➔ + ⇒ † 14.8
39 77/F L861Q PE (−) ➔ G ➔ − ➔ E ➔ − ➔ E ➔ † 3.9
40 77/F G719C PE (−) ➔ G ➔ − ➔ E ➔ − ⇒ † 36.2
41 61/F L858R CSF (−) ➔ G, E ➔ − ➔ H-E ➔ + ➔ H-E ➔ † 24.4
42 52/M L858R CSF (−) ➔ G ➔ − ➔ E ➔ − ➔ E ➔ † 22.3
22 67/F L858R CSF (−) ➔ E ➔ − ➔ E ➔ − ➔ H-E ➔ † 11.4
7 56/F Del-19 CSF (−) ➔ E ➔ − ➔ H-E ➔ − ➔ H-E ➔ † 7.6
13 63/F L858R CSF (−) ➔ G ➔ − ➔ E ➔ − ➔ E ➔ † 36.0
43 65/F L858R CSF (−) ➔ G ➔ − ➔ E ➔ − ➔ E ➔ † 6.8
Black arrows (➔ × ➔) represent TKI administration and white arrows (⇒) no TKI exposure.
Parentheses mean T790M status at the diagnostic biopsy in thoracic lesions.
Patient 32 had a de novo T790M mutation at the surgical specimen, but it was not detected at recurrence.
TKI, tyrosine kinase inhibitor; PPS, postprogression survival; F, female; M, male; PE, pleural effusion; CSF, cerebrospinal fluid; G, geﬁtinib; E, erlotinib; A, afatinib; III, third-
generation EGFR-TKI; B, bevacizumab; H-E, high-dose erlotinib;†, patient death.
TABLE 4. Efficacy of EGFR-TKI Rechallenge after T790M Disappearance
Patient Age/Sex Sensitive Mutation Rechallenge TKI TKI-free interval Response PFS (mo) PPS (mo)
24 61/M L858R Geﬁtinib 12.0 PR 6.0 48.0+
31 82/M L858R Geﬁtinib 12.0 PR 9.6 34.1+
32 73/F L858R Geﬁtinib 13.8 PR 4.5+ 24.9+
33 76/F Del-19 Geﬁtinib 15.9 SD 5.7 25.5
34 84/M L858R Erlotinib 3.9 PRa 1.3b 13.3
aUnconﬁrmed PR.
bThe patient died because of heart and renal failure despite response to erlotinib.
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; PFS, progression-free interval; PPS, postprogression survival: PR, partial response; SD, stable disease; F, 
female; M, male.
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cells can repopulate more quickly than TKI-resistant cells, 
and tumors may regain their sensitivity to TKI. Heon et al. 
demonstrated that 16 patients with a longer TKI-free interval 
(>6 mo) were able to obtain greater beneﬁt from erlotinib 
rechallenge than eight patients with a shorter TKI-free 
interval (≤6 mo; median time to progression: 4.4 mo versus 
1.9 mo, p = 0.026).41 In four of our ﬁve patients (24, and 
31–33), rebiopsy 6 months after TKI withdrawal revealed 
still T790M-positive, but T790M changed to negative follow-
ing a further 6 months. Longer TKI-free intervals (presum-
ably interspersed with cytotoxic chemotherapies) may reduce 
TKI-resistant clones and induce the restoration of EGFR-TKI 
sensitivity. T790M disappearance represents a signiﬁcant 
reduction of TKI-resistant, T790M-positive clones, which 
could be a predictive marker for TKI rechallenge.
Our study includes several limitations. First, it is ret-
rospective and small sample size. The response and PFS 
were evaluated using Response Evaluation Criteria in Solid 
Tumors, but some biases were inevitable because of the small 
retrospective nature. Second, timings were different among 
each rebiopsy in some cases who received rebiopsies to mul-
tiple sites. These timing differences might regard a temporal 
T790M change as a spatial T790M difference. On the other 
hand, multiple site rebiopsies were simultaneously performed 
in some cases, and spatial T790M differences were deﬁni-
tively proved in these cases (e.g., pleural effusion and CSF 
were collected on the same day, and T790M was detected in 
pleural effusion, but not in CSF). Third, repeated rebiopsies 
were done without consideration of TKI exposure. T790M is 
mediated by TKI exposure, and thus T790M status can vary by 
the timing of rebiopsy and whether “on” or “off ” of EGFR-
TKI at the time of rebiopsy.
In conclusion, T790M status in an individual patient can 
be spatiotemporally heterogeneous because of selective pres-
sure from EGFR-TKI. T790M is not only a resistant mecha-
nism but also a clinically signiﬁcant biomarker after acquired 
resistance to EGFR-TKI. Upcoming third-generation EGFR-
TKIs will assign T790M from a “prognostic” marker to a 
“predictive” marker. T790M will be clinically more impor-
tant, and rebiopsy will become more essential in clinical prac-
tice. Further studies are warranted to better understand this 
spatiotemporal T790M heterogeneity and its interaction with 
EGFR-TKI therapy.
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